MCID: ALC004
MIFTS: 63

Alcohol Abuse

Categories: Mental diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Alcohol Abuse

Summaries for Alcohol Abuse

Genetics Home Reference : 25 Alcohol use disorder is a diagnosis made when an individual has severe problems related to drinking alcohol. Alcohol use disorder can cause major health, social, and economic problems, and can endanger affected individuals and others through behaviors prompted by impaired decision-making and lowered inhibitions, such as aggression, unprotected sex, or driving while intoxicated.

MalaCards based summary : Alcohol Abuse, also known as alcohol use disorder, is related to viral hepatitis and alcoholic hepatitis, and has symptoms including hangover from any alcohol or other drugs substance and hangover from alcohol. An important gene associated with Alcohol Abuse is CYP2E1 (Cytochrome P450 Family 2 Subfamily E Member 1), and among its related pathways/superpathways are Porphyrin and chlorophyll metabolism and Circadian rythm related genes. The drugs Bupropion and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and testes, and related phenotypes are Decreased shRNA abundance and Decreased shRNA abundance

Disease Ontology : 12 A substance abuse that involves the recurring use of alcoholic beverages despite negative consequences.

Wikipedia : 76 Alcohol abuse is a previous psychiatric diagnosis in which there is recurring harmful use of alcohol... more...

Related Diseases for Alcohol Abuse

Diseases in the Alcohol Abuse family:

Alcohol Sensitivity, Acute

Diseases related to Alcohol Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 178)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 30.5 ABCB7 GGT1 GPT SLC17A5
2 alcoholic hepatitis 30.3 CYP2E1 GPT SLC17A5
3 liver disease 30.0 ABCB7 CYP2E1 GGT1 GPT SLC17A5 TF
4 alcoholic liver cirrhosis 30.0 ALDH2 CYP2E1 SLC17A5 TF
5 conduct disorder 30.0 ALDH2 DRD2 DRD4 SLC6A4
6 delusional disorder 29.9 DRD2 DRD3 DRD4
7 gilles de la tourette syndrome 29.9 BDNF DRD2 DRD4
8 cocaine dependence 29.9 DRD2 DRD3 SLC6A4
9 pathological gambling 29.9 DRD2 DRD3 DRD4 SLC6A4
10 anxiety 29.7 BDNF CNR1 SLC6A4
11 eating disorder 29.7 BDNF CNR1 DRD2 SLC6A4
12 cocaine abuse 29.5 DRD2 PRL SLC6A4
13 liver cirrhosis 29.5 ALDH2 CYP2E1 GGT1 GPT SLC17A5 TF
14 alexithymia 29.2 ANKK1 DRD2 SLC6A4
15 mood disorder 29.2 BDNF DRD2 DRD3 DRD4 SLC6A4
16 anorexia nervosa 29.0 BDNF PRL SLC6A4
17 personality disorder 28.8 ALDH2 BDNF DRD2 DRD3 DRD4 SLC6A4
18 antisocial personality disorder 28.7 ALDH2 ANKK1 DRD2 SLC6A4
19 schizophrenia 27.7 BDNF CNR1 DRD2 DRD3 DRD4 PRL
20 bipolar disorder 27.7 BDNF DRD2 DRD3 DRD4 GGT1 PRL
21 disease of mental health 27.6 ALDH2 BDNF CNR1 DRD2 DRD3 DRD4
22 psychotic disorder 27.1 BDNF CNR1 DRD2 DRD3 DRD4 PRL
23 substance abuse 27.1 BDNF DRD2 DRD3 DRD4 GABRA2 PRL
24 alcohol dependence 25.1 AKR1A1 ALDH2 ALDH9A1 ANKK1 BDNF CNR1
25 fetal alcohol syndrome 12.5
26 wernicke-korsakoff syndrome 11.3
27 osteonecrosis 11.3
28 cerebellar degeneration 11.1
29 hyperlipoproteinemia, type v 11.0
30 lipomatosis, multiple symmetric 11.0
31 dystonia 11, myoclonic 11.0
32 nuchal bleb, familial 11.0
33 nonalcoholic fatty liver disease 11.0
34 beriberi 11.0
35 megalocytic interstitial nephritis 11.0
36 atrial fibrillation and stroke 11.0
37 cerebral beriberi 11.0
38 hypersomnia 11.0
39 korsakoff's amnesic syndrome 11.0
40 tremor 11.0
41 paraquat poisoning 10.9 GPT SLC17A5
42 pyridoxine deficiency 10.8 GPT SLC17A5
43 kwashiorkor 10.7 GPT SLC17A5 TF
44 analbuminemia 10.7 GPT SLC17A5 TF
45 bilirubin metabolic disorder 10.7 GGT1 GPT SLC17A5
46 obstructive jaundice 10.7 GGT1 GPT SLC17A5
47 methanol poisoning 10.6 AKR1A1 CYP2E1
48 alcohol-induced mental disorder 10.6 DRD2 SLC6A4
49 hepatic tuberculosis 10.6 GGT1 GPT
50 wilson disease 10.6 DRD2 GPT TF

Comorbidity relations with Alcohol Abuse via Phenotypic Disease Network (PDN): (show all 20)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcohol-Induced Mental Disorder
Alcoholic Cardiomyopathy Alcoholic Gastritis
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Alcoholic Neuropathy Cocaine Abuse
Deficiency Anemia Familial Atrial Fibrillation
Fatty Liver Disease Hepatic Encephalopathy
Hypertension, Essential Major Depressive Disorder
Pancreatitis, Hereditary Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Alcohol Abuse:



Diseases related to Alcohol Abuse

Symptoms & Phenotypes for Alcohol Abuse

UMLS symptoms related to Alcohol Abuse:


hangover from any alcohol or other drugs substance, hangover from alcohol

GenomeRNAi Phenotypes related to Alcohol Abuse according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance GR00251-A-1 9.28 ALDH9A1 CYP2E1
2 Decreased shRNA abundance GR00251-A-2 9.28 ALDH9A1 CYP2E1
3 Decreased shRNA abundance GR00297-A 9.28 CYP2E1 GABRA2 ABCB7 AKR1A1 ALDH9A1
4 Decreased melanin production GR00056-A 9.13 SLC17A5 UROD ALDH9A1

MGI Mouse Phenotypes related to Alcohol Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 TF UROD PRL SLC17A5 SLC6A4 DRD4
2 behavior/neurological MP:0005386 10.18 PRL SLC17A5 SLC6A4 DRD3 ALDH2 DRD4
3 growth/size/body region MP:0005378 10.06 SLC6A4 TF GGT1 SLC17A5 DRD3 ALDH2
4 integument MP:0010771 9.85 SLC6A4 GGT1 PRL ALDH2 ALDH9A1 BDNF
5 mortality/aging MP:0010768 9.83 TF UROD SLC17A5 SLC6A4 ALDH2 BDNF
6 nervous system MP:0003631 9.4 SLC6A4 PRL SLC17A5 DRD3 ALDH2 DRD4

Drugs & Therapeutics for Alcohol Abuse

Drugs for Alcohol Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupropion Approved Phase 4,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
3
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
4
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
5
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2 77337-76-9 71158
6
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
7
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-12-2 119
8
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
9
Clonidine Approved Phase 4,Early Phase 1 4205-90-7 2803
10 Nefopam Approved, Investigational Phase 4 13669-70-0
11
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
12
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
15
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 16590-41-3 5360515
16
Topiramate Approved Phase 4,Phase 2,Phase 3,Not Applicable 97240-79-4 5284627
17
Ondansetron Approved Phase 4,Phase 2,Phase 3,Phase 1 99614-02-5 4595
18
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
19
Chlorzoxazone Approved Phase 4,Not Applicable 95-25-0 2733
20
Methylphenidate Approved, Investigational Phase 4,Phase 1,Early Phase 1 113-45-1 4158
21
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 249296-44-4 5310966
22
Dutasteride Approved, Investigational Phase 4,Not Applicable 164656-23-9 152945 6918296
23
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 2 68291-97-4 5734
24
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
25
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
26
Haloperidol Approved Phase 4 52-86-8 3559
27
Lorazepam Approved Phase 4,Phase 2 846-49-1 3958
28
Ribavirin Approved Phase 4,Phase 2 36791-04-5 37542
29
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
30
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
31
Disulfiram Approved Phase 4,Phase 2 97-77-8 3117
32
Sertraline Approved Phase 4,Phase 2,Phase 1 79617-96-2 68617
33
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 54-11-5 942 89594
34
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 52485-79-7 40400 644073
35
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
36
Methadone Approved Phase 4,Phase 2 76-99-3 4095
37
Naloxone Approved, Vet_approved Phase 4,Phase 3 465-65-6 5284596
38
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1 50-36-2 5760 446220
39
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-56-6 439302 53477758
40
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
41
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
42
Clozapine Approved Phase 4 5786-21-0 2818
43
Heroin Approved, Illicit, Investigational Phase 4 561-27-3 5462328
44 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45
Choline Approved, Nutraceutical Phase 4,Phase 1,Phase 2,Not Applicable 62-49-7 305
46
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 2 56-86-0 33032
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 59-30-3 6037
48
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
49
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
50 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 781)
# Name Status NCT ID Phase Drugs
1 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
2 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
3 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
4 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
5 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
6 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse Completed NCT00190957 Phase 4 Atomoxetine;placebo
7 Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence Completed NCT00223249 Phase 4 Quetiapine
8 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
9 Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
10 Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake Completed NCT01342341 Phase 4 Parafon Forte
11 Adolescent Family-Based Alcohol Prevention Completed NCT00858065 Phase 4
12 Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults Completed NCT00550394 Phase 4 quetiapine and placebo;Quetiapine and Topiramate
13 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
14 Bupropion as a Smoking Cessation Aid in Alcoholics Completed NCT00044434 Phase 4 bupropion (Wellbutrin)
15 Varenicline in Drug Treatment Completed NCT01286584 Phase 4 varenicline;placebo
16 Dutasteride for the Reduction of Alcohol Use in Male Drinkers Completed NCT01262287 Phase 4 Dutasteride;Placebo
17 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
18 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
19 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
20 AID-trial Assertive Intervention After Deliberate Self-harm Completed NCT00700089 Phase 4
21 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
22 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
23 A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Completed NCT00457366 Phase 4 Quetiapine;Cocktail (Haloperidol, Lorazepam, Cogentin)
24 Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity Completed NCT00957866 Phase 4 Pegylated Interferons (Peg-IFN) and Ribavirin
25 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
26 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
27 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
28 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
29 Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine) Completed NCT00006204 Phase 4 naltrexone (Revia);fluoxetine (Prozac)
30 Naltrexone, Craving, and Drinking Completed NCT00006203 Phase 4 naltrexone (Revia)
31 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
32 Behavior and Naltrexone Treatment for Alcoholics Completed NCT00000449 Phase 4 naltrexone (Revia)
33 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
34 Drug Therapy for Alcohol Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
35 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
36 Topiramate Treatment of Problem Drinkers Completed NCT00626925 Phase 4 topiramate;placebo
37 Biomarker Study of Acamprosate in Schizophrenia Completed NCT00688324 Phase 4 Acamprosate
38 The Whole Day First Grade Program Completed NCT00257088 Phase 4
39 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
40 Pharmacogenetic Response to Naltrexone For Alcohol Dependence Completed NCT00831272 Phase 4 naltrexone;Placebo
41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
42 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
43 Targeted Naltrexone for Problem Drinkers Completed NCT00369408 Phase 4 Naltrexone;placebo
44 Sertraline Pharmacotherapy for Alcoholism Subtypes Completed NCT00368550 Phase 4 Sertraline;Placebo
45 The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects Completed NCT00329407 Phase 4 Topiramate (Topamax)
46 Treatment of Alcohol Withdrawal in Hospital Patients Completed NCT00249366 Phase 4 Lorazepam (drug);Lorazepam
47 Combination Nicotine Replacement for Alcoholic Smokers Completed NCT00064844 Phase 4
48 Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone) Completed NCT00006489 Phase 4 Naltrexone;Placebo
49 Post-Treatment Effects of Naltrexone Completed NCT00006449 Phase 4 naltrexone (Revia)
50 Behavioral Counseling for Alcohol Dependent Smokers (Nicotine Patch) Completed NCT00004551 Phase 4 nicotine replacement patch

Search NIH Clinical Center for Alcohol Abuse

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: alcoholism

Genetic Tests for Alcohol Abuse

Anatomical Context for Alcohol Abuse

MalaCards organs/tissues related to Alcohol Abuse:

41
Brain, Liver, Testes, Lung, Bone, Heart, Breast

Publications for Alcohol Abuse

Articles related to Alcohol Abuse:

(show top 50) (show all 738)
# Title Authors Year
1
Genome wide analysis of rare copy number variations in alcohol abuse or dependence. ( 29890507 )
2018
2
Effect of Chronic Alcohol Abuse on Anabolic and Catabolic Signaling Pathways in Human Skeletal Muscle. ( 29044624 )
2018
3
Cognitive impairment associated with cocaine use: The role of co-existent alcohol abuse/dependence. ( 29886366 )
2018
4
The Alcohol-Abuse Drug Disulfiram Targets NPL4 to Exert Antitumor Effects. ( 29247017 )
2018
5
Do general practitioners record alcohol abuse in the electronic medical records? A comparison of survey and medical record data. ( 29301406 )
2018
6
Valentin Magnan and Sergey Korsakov: French and Russian pioneers in the study of alcohol abuse. ( 29469655 )
2018
7
Hypokalemia associated with pseudo-Cushing's syndrome and magnesium deficiency induced by chronic alcohol abuse. ( 29450857 )
2018
8
Alcohol abuse numbers in Spain: nearly 420,000 deaths in current century. ( 29859629 )
2018
9
Everyday memory problems in alcohol abuse and dependence: Frequency, patterns and patient-proxy agreement. ( 29360054 )
2018
10
Effects of Alcohol Abuse on Proliferating Cells, Stem/Progenitor Cells, and Immature Neurons in the Adult Human Hippocampus. ( 29052615 )
2018
11
Single Nucleotide Polymorphisms in the Vitamin D Receptor Gene (<i>VDR</i>) May Have an Impact on Acute Pancreatitis (AP) Development: A Prospective Study in Populations of AP Patients and Alcohol-Abuse Controls. ( 29966312 )
2018
12
Hip osteonecroses treated with calcium sulfate-calcium phosphate bone graft substitute have different results according to the cause of osteonecrosis: alcohol abuse or corticosteroid-induced. ( 29550914 )
2018
13
Identifying adolescents with alcohol use disorder: Optimal screening using the National Institute on Alcohol Abuse and Alcoholism screening guide. ( 29975071 )
2018
14
Cancer: Anticancer effects of alcohol abuse drug. ( 29386611 )
2018
15
Development and validation of a Partial Least Squares-Discriminant Analysis (PLS-DA) model based on the determination of ethyl glucuronide (EtG) and fatty acid ethyl esters (FAEEs) in hair for the diagnosis of chronic alcohol abuse. ( 29174052 )
2018
16
Elevated inflammation in association with alcohol abuse among Blacks but not Whites: results from the MIDUS biomarker study. ( 29230616 )
2017
17
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. ( 29211715 )
2017
18
Dissecting the Role of Disturbed ER-Golgi Trafficking in Antivirals and Alcohol Abuse-Induced Pathogenesis of Liver Disorders. ( 29399658 )
2017
19
Traumatic Brain Injuries during Development: Implications for Alcohol Abuse. ( 28775682 )
2017
20
More Likely to Dropout, but What if They Don't? Partner Violence Offenders With Alcohol Abuse Problems Completing Batterer Intervention Programs. ( 29294698 )
2017
21
Adverse Childhood Experiences (ACEs) and Alcohol Abuse among South Carolina Adults. ( 29185846 )
2017
22
Re-evaluation of the reward comparison hypothesis for alcohol abuse. ( 28606627 )
2017
23
The association between alcohol abuse and neuroendocrine system dysregulation: Race differences in a National sample. ( 28751021 )
2017
24
Mood disorder, anxiety, and suicide risk among subjects with alcohol abuse and/or dependence: a population-based study. ( 28658442 )
2017
25
Correction: Experiences of severe childhood maltreatment, depression, anxiety and alcohol abuse among adults in Finland. ( 28640921 )
2017
26
The effects of seasonal affective disorder and alcohol abuse on sleep and snoring functions in a population-based study in Finland. ( 28901656 )
2017
27
Burden of Alcohol Abuse or Dependence Among Long-Term Opioid Users with Chronic Noncancer Pain. ( 28650247 )
2017
28
The effects of residential dual diagnosis treatment on alcohol abuse. ( 28868159 )
2017
29
Favorable effects of motivational interviewing and support in a patient with schizophrenia and alcohol abuse. ( 29264040 )
2017
30
Theoretical Foundations of Appeals Used in Alcohol-Abuse and Drunk-Driving Public Service Announcements in the United States, 1995-2010. ( 28511551 )
2017
31
Alcohol Abuse is Associated with Enhanced Pulmonary and Systemic Xanthine Oxidoreductase Activity. ( 28839105 )
2017
32
Patterns of Alcohol Abuse, Depression, and Intimate Partner Violence Among Township Mothers in South Africa Over 5 Years. ( 29027039 )
2017
33
Genetic divergence in the transcriptional engram of chronic alcohol abuse: A laser-capture RNA-seq study of the mouse mesocorticolimbic system. ( 27894806 )
2017
34
Experiences of severe childhood maltreatment, depression, anxiety and alcohol abuse among adults in Finland. ( 28481912 )
2017
35
The Power of Negative Mood in Predicting Posttraumatic Stress Disorder and Alcohol Abuse Comorbidity. ( 29022727 )
2017
36
Solid-phase extraction of the alcohol abuse biomarker phosphatidylethanol using newly synthesized polymeric sorbent materials containing quaternary heterocyclic groups. ( 28890270 )
2017
37
College Students' Responses to Emotional Anti-Alcohol Abuse Media Messages: Should We Scare or Amuse Them? ( 28705030 )
2017
38
Alcohol Abuse and Cardiac Disease. ( 28057245 )
2017
39
Sporadic Porphyria Cutanea Tarda Induced by Alcohol Abuse. ( 28776562 )
2017
40
Seasonal affective disorder and alcohol abuse disorder in a population-based study. ( 28364591 )
2017
41
Chronic alcohol abuse in men alters bone mechanical properties by affecting both tissue mechanical properties and microarchitectural parameters. ( 28410916 )
2017
42
Drinking Status Between Ages 50 and 55 for Men From the San Diego Prospective Study Who Developed DSM-IV Alcohol Abuse or Dependence in Prior Follow-Ups. ( 28728633 )
2017
43
Association of Physical Activity with Alcohol Abuse and Dependence in a Nationally-Representative U.S. Sample. ( 28704120 )
2017
44
Testing the effectiveness of a transdiagnostic treatment approach in reducing violence and alcohol abuse among families in Zambia: study protocol of the Violence and Alcohol Treatment (VATU) trial. ( 29230314 )
2017
45
Gender Differences in Suicidal Behaviors: Mediation Role of Psychological Distress Between Alcohol Abuse/Dependence and Suicidal Behaviors. ( 28805555 )
2017
46
Zinc deficiency as a mediator of toxic effects of alcohol abuse. ( 29177978 )
2017
47
The Role of the Melanocortin System in Drug and Alcohol Abuse. ( 29056149 )
2017
48
Contextual Factors Related to Alcohol Abuse Among Intimate Partner Violence Offenders. ( 27759488 )
2017
49
Chronic Alcohol Abuse Leads to Low Bone Mass with No General Loss of Bone Structure or Bone Mechanical Strength(). ( 27864963 )
2017
50
CERVICAL TRANSFORMATION IN ALCOHOL ABUSE PATIENTS. ( 29099694 )
2017

Variations for Alcohol Abuse

Expression for Alcohol Abuse

LifeMap Discovery
Genes differentially expressed in tissues of Alcohol Abuse patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 ADAMTS18 ADAM metallopeptidase with thrombospondin type 1 motif, 18 Brain - 3.66 0.005
Search GEO for disease gene expression data for Alcohol Abuse.

Pathways for Alcohol Abuse

Pathways related to Alcohol Abuse according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.91 AKR1A1 ALDH2 ALDH9A1 UROD
3
Show member pathways
11.67 DRD2 DRD3 DRD4
4 11.59 CNR1 DRD3 DRD4
5
Show member pathways
11.55 DRD2 DRD3 DRD4
6
Show member pathways
11.17 AKR1A1 ALDH2 ALDH9A1 CYP2E1
7 10.92 AKR1A1 ALDH2 ALDH9A1
8
Show member pathways
10.5 ALDH2 CYP2E1

GO Terms for Alcohol Abuse

Cellular components related to Alcohol Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 CNR1 DRD2 DRD3 DRD4 GABRA2 SLC17A5
2 endocytic vesicle GO:0030139 8.8 DRD2 DRD3 TF

Biological processes related to Alcohol Abuse according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.94 CYP2E1 DRD2 DRD3 SLC6A4
2 response to ethanol GO:0045471 9.8 CNR1 CYP2E1 DRD2 DRD3
3 memory GO:0007613 9.77 BDNF CNR1 SLC6A4
4 social behavior GO:0035176 9.76 DRD3 DRD4 SLC6A4
5 response to cocaine GO:0042220 9.74 CNR1 DRD2 DRD3
6 response to morphine GO:0043278 9.69 CNR1 DRD2 DRD3
7 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD3
8 negative regulation of blood pressure GO:0045776 9.65 CNR1 DRD2 DRD3
9 behavioral response to ethanol GO:0048149 9.64 DRD2 DRD4
10 positive regulation of renal sodium excretion GO:0035815 9.63 DRD2 DRD3
11 neurotransmitter biosynthetic process GO:0042136 9.63 ALDH9A1 SLC6A4
12 response to amphetamine GO:0001975 9.63 DRD2 DRD3 DRD4
13 negative regulation of voltage-gated calcium channel activity GO:1901386 9.62 DRD2 DRD4
14 regulation of synaptic transmission, GABAergic GO:0032228 9.62 CNR1 DRD2
15 prepulse inhibition GO:0060134 9.61 DRD2 DRD3
16 G-protein coupled receptor internalization GO:0002031 9.61 DRD2 DRD3
17 cellular aldehyde metabolic process GO:0006081 9.6 AKR1A1 ALDH9A1
18 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.58 DRD2 DRD3
19 arachidonic acid secretion GO:0050482 9.58 DRD2 DRD3 DRD4
20 acid secretion GO:0046717 9.56 DRD2 DRD3
21 negative regulation of dopamine secretion GO:0033602 9.55 CNR1 DRD2
22 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.54 DRD2 DRD4
23 behavioral response to cocaine GO:0048148 9.54 DRD2 DRD3 DRD4
24 negative regulation of dopamine receptor signaling pathway GO:0060160 9.52 DRD2 DRD3
25 dopamine receptor signaling pathway GO:0007212 9.5 DRD2 DRD3 DRD4
26 regulation of locomotion involved in locomotory behavior GO:0090325 9.43 DRD2 DRD3
27 negative regulation of protein secretion GO:0050709 9.43 DRD2 DRD3 DRD4
28 dopamine metabolic process GO:0042417 9.33 DRD2 DRD3 DRD4
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD2 DRD3 DRD4
30 response to histamine GO:0034776 8.8 DRD2 DRD3 DRD4

Molecular functions related to Alcohol Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.56 CNR1 DRD2 DRD3 DRD4
2 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
3 aldehyde dehydrogenase (NAD) activity GO:0004029 9.32 ALDH2 ALDH9A1
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Alcohol Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek